Lilly backs $45M investment for mRNA cancer immunotherapy startup

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million. New investor FPV led the round, with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate.